Close every open loop after a clinical study

Name the endpoint you reached

Your last visit may end your scheduled participation while the study continues for other participants. Record the last dose or device-use date, your final required activity, and any remaining safety contact. Ask the site to confirm each date in writing.

ClinicalTrials.gov defines the registry milestones (opens in a new tab). Analysis and publication follow separate schedules. Ask which milestone controls unblinding, individual-result return, and the study’s results message.

Complete the safety closeout

Ask the study clinician to list the final examinations, laboratory tests, observation periods, symptom-reporting window, medication instructions, activity restrictions, and emergency contact. Report new or continuing symptoms through the study’s approved path. Seek emergency care for an emergency, then follow the consent form’s study-notification instructions.

Within its stated scope—interventional trials of investigational products intended for regulatory submission—FDA-adopted Good Clinical Practice guidance (opens in a new tab) recommends following the protocol and related documents when a participant reaches the routine end of a trial. Its principles may also apply to other interventional clinical trials of investigational products. Confirm whether long-term calls, record review, pregnancy follow-up, imaging, or device monitoring remain part of your participation. Ask which activities address safety, which collect research outcomes, and which carry compensation or reimbursement.

Return study products and equipment under written instructions

Inventory unused study drug, packaging, reusable devices, chargers, sensors, paper diaries, identification cards, and shipping materials. Wait for the site’s written return or disposal instructions. Record the quantity, handoff date, tracking number, and receipt. Keep photographs free of names, subject numbers, and other health information.

FDA’s investigator-responsibility page (opens in a new tab) assigns investigators responsibility for returning or otherwise disposing of unused investigational drug supplies when an investigation ends. FDA device-investigation guidance (opens in a new tab) describes corresponding investigator and sponsor duties for remaining investigational devices. Do not discard, mail, transfer, wipe, or uninstall study property without instructions.

For an implanted device or removal that requires a procedure, obtain a written monitoring, maintenance, or removal plan from the study clinician. For an app or loaned digital device, confirm that required entries synchronized before deletion. Ask how the site removes personal accounts, saved networks, photographs, and files from returned equipment.

Reconcile accrued payment and reimbursement

Create a final ledger with every completed visit, call, diary period, confinement day, procedure, and approved expense. Put the amount promised, amount received, issue date, payment method, and missing documentation on one line for each item. Submit receipts before the stated deadline and keep copies.

For FDA-regulated research, FDA payment guidance (opens in a new tab) states that payment credit should accrue as participation progresses and that the entire amount should not depend on completing the full study. A small completion incentive may have separate IRB-reviewed terms. Ask the site to distinguish accrued compensation, a completion incentive, expense reimbursement, and any amount under review.

Confirm the payment processor, expected release date, replacement process, card expiration or fees, and payer name for an expected tax form. Send a dated, itemized discrepancy to the coordinator or payment office. Use the participant-rights or IRB contact when written terms conflict or payment pressure affects voluntary choice.

Map what continues for data and specimens

Separate four categories: data already collected for the main study, new information the team may seek later, identifiable or coded specimens still in storage, and data or specimens already shared or analyzed. Ask which consent or HIPAA authorization covers each category, how long it remains, who can receive it, and whether identifiers can still be linked to you.

If you want to stop optional future record access, recontact, or specimen use, ask for the exact withdrawal or revocation process. OHRP withdrawal guidance (opens in a new tab) explains that HHS-covered researchers may retain and analyze already collected data within the approved study, and that FDA-regulated trial data collected before withdrawal remain in the trial database. Federal advisory guidance on stored biospecimens (opens in a new tab) explains that withdrawal from future specimen research can have practical limits after specimens have been distributed, analyses completed, or identifiers removed.

Ask the repository to state what it can still do, what it has already done, and what it cannot reverse. Request written confirmation of a change. Record whether future work may include genetic or whole-genome analysis, commercial development, sharing with other institutions, or recontact.

Request individual results and treatment assignment

For trials within its stated scope, FDA-adopted Good Clinical Practice guidance (opens in a new tab) recommends, when relevant, informing participants of trial results and the treatment received after unblinding when the sponsor makes that information available, while respecting whether the participant wants to know. Ask the site to record your preference, contact method, expected timing, and backup contact.

Return practices vary across clinical research. NIH’s return-of-results resources (opens in a new tab) distinguish participant-specific results from summary findings. Ask which results arrive automatically and which require a request.

HHS explains the HIPAA access rule (opens in a new tab) for health information held in a designated record set. If access was suspended during a treatment trial under the conditions HHS describes, it is reinstated at the trial’s conclusion. This does not place every research assay or sponsor data file in a designated record set. Ask the covered provider which records are available and how to request them.

Track registry results and publications

Save the NCT number, official title, sponsor, study URL, and current primary and study completion dates. Open the same record later and check the Results tab and Record History. A posted results record can include participant flow, baseline characteristics, outcome measures, adverse events, limitations, and publications. Use the ClinicalTrials.gov results guide (opens in a new tab) to read each section.

For applicable clinical trials subject to the federal reporting rule, the standard results-submission deadline is no later than one year after the primary completion date. Certifications, extensions, and other rules can change timing. Some studies are not subject to that requirement. A record without posted results can mean the study continues, the deadline has not passed, an extension applies, results are undergoing quality-control review, submission is not required, or the responsible party is overdue or noncompliant. ClinicalTrials.gov explains the deadline and exceptions (opens in a new tab).

Set a reminder based on the actual primary completion date, then check the record periodically. Review publications listed there, but match the NCT number, study population, intervention, outcomes, enrollment, and sponsor before treating a paper as the main report.

Arrange continued access or a transition to regular care

Ask before the final dose or procedure whether the intervention stops, tapers, changes to an approved treatment, continues in an extension study, or requires monitoring after use. Schedule the next treating-clinician appointment before the study’s care ends. Request the intervention name, assignment when available, dose or device details, exposure dates, clinically returned results, adverse-event summary, and follow-up recommendations for that clinician.

Continued access to an investigational product is not automatic. FDA patient guidance (opens in a new tab) describes expanded access as a potential pathway for a serious or life-threatening condition when no comparable or satisfactory therapy is available. A licensed physician, the company, an IRB, and FDA must each take the required role, and the company is not required to provide the product outside a trial.

Ask about an extension protocol, another recruiting trial, expanded access, and approved alternatives as separate options. Review personal treatment decisions with your clinician. Confirm who handles refills, device service, routine monitoring, and urgent questions after the research team’s role ends.

Keep a compact closeout file

Keep the signed consent and later revisions, study identifiers, investigator and rights contacts, intervention record, final safety instructions, returned-product receipt, payment reconciliation, expense receipts, individual results, and result-request messages. Add the date your participation ended and the next registry reminder.

Store the file in a protected location. Remove health details from shared calendars and task apps. Keep the study’s safety contact available for the period stated in the closeout instructions. Update the site when your email, telephone number, mailing address, or result preference changes.

Complete the 20-point closeout checklist

The page code does not save or send checks to Clinical Forage. A browser may restore form values. Use Clear checks before leaving a shared device.